---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130449"
form_type: "8-K"
ticker: "EIKN"
cik: "0001861123"
company_name: "Eikon Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:47.848449+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M

## Summary
- Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.
- Cash, cash equivalents and marketable securities $336M as of Dec 31, 2025; added $381.2M from IPO in Feb 2026.
- Completed enrollment of TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 NSCLC; data expected 2H 2026.
- R&D expenses $65.2M in Q4 2025 (+21% YoY); $250.3M for FY2025 (+22% YoY).
- Elected David W. Meline (former CFO of Moderna, Amgen, 3M) as independent director in December 2025.

## SEC filing metadata
- accession: 0001193125-26-130449
- form_type: 8-K
- ticker: EIKN
- cik: 0001861123
- company_name: Eikon Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/0001193125-26-130449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/d244624d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130449
- JSON: https://secwatch.observer/filing/0001193125-26-130449.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130449.txt

## Key facts
- Earnings Releases
  Eikon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025.
  - Period: fourth quarter and full year ended December 31, 2025
  - Net income: Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025
  - Result: reported results
  source text: On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/0001193125-26-130449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.